On Friday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was 6.41% up from the session before settling in for the closing price of $1.17. A 52-week range for TSHA has been $1.05 – $4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 94.30% over the past five years. When this article was written, the company’s average yearly earnings per share was at -1.42%. With a float of $165.01 million, this company’s outstanding shares have now reached $204.94 million.
Let’s look at the performance matrix of the company that is accounted for 73 employees. In terms of profitability, gross margin is 100.0%, operating margin of -1097.55%, and the pretax margin is -1071.62%.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 19.51%, while institutional ownership is 77.26%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.46% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc (NASDAQ: TSHA) saw its 5-day average volume 1.63 million, a negative change from its year-to-date volume of 2.14 million. As of the previous 9 days, the stock’s Stochastic %D was 28.53%. Additionally, its Average True Range was 0.16.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 8.63%, which indicates a significant decrease from 21.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.04% in the past 14 days, which was higher than the 98.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5974, while its 200-day Moving Average is $1.9552. Nevertheless, the first resistance level for the watch stands at $1.2967 in the near term. At $1.3483, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4267. If the price goes on to break the first support level at $1.1667, it is likely to go to the next support level at $1.0883. The third support level lies at $1.0367 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 205,002K outstanding shares of the company, which has a market capitalization of 255.23 million. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 2,020 K while its last quarter net income were -18,780 K.
